413 related articles for article (PubMed ID: 29926707)
1. Experimental In Vivo Models of Bacterial Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Jeong YJ; Park SK; Yoon SJ; Park YJ; Lee MS
J Microbiol Biotechnol; 2018 Sep; 28(9):1413-1425. PubMed ID: 29926707
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
[TBL] [Abstract][Full Text] [Related]
3. Role of Shiga/Vero toxins in pathogenesis.
Obata F; Obrig T
Microbiol Spectr; 2014 Jun; 2(3):. PubMed ID: 25530918
[TBL] [Abstract][Full Text] [Related]
4. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome.
Brigotti M; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Valerii MC; Spisni E
Int J Med Microbiol; 2018 Oct; 308(7):940-946. PubMed ID: 29983334
[TBL] [Abstract][Full Text] [Related]
5. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.
López EL; Contrini MM; Glatstein E; Ayala SG; Santoro R; Ezcurra G; Teplitz E; Matsumoto Y; Sato H; Sakai K; Katsuura Y; Hoshide S; Morita T; Harning R; Brookman S
Pediatr Infect Dis J; 2012 Jan; 31(1):20-4. PubMed ID: 21829137
[TBL] [Abstract][Full Text] [Related]
6. [Role of the Shiga toxin in the hemolytic uremic syndrome].
Creydt VP; Nuñez P; Boccoli J; Silberstein C; Zotta E; Goldstein J; Ibarra C
Medicina (B Aires); 2006; 66 Suppl 3():11-5. PubMed ID: 17354471
[TBL] [Abstract][Full Text] [Related]
7. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.
Ardissino G; Vignati C; Masia C; Capone V; Colombo R; Tel F; Daprai L; Testa S; Dodaro A; Paglialonga F; Luini M; Brigotti M; Picicco D; Baldioli C; Pagani F; Ceruti R; Tommasi P; Possenti I; Cresseri D; Consonni D; Montini G; Arghittu M;
J Pediatr; 2021 Oct; 237():34-40.e1. PubMed ID: 34197890
[TBL] [Abstract][Full Text] [Related]
8. New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli.
Melton-Celsa AR; O'Brien AD
Microbiol Spectr; 2014 Oct; 2(5):. PubMed ID: 26104346
[TBL] [Abstract][Full Text] [Related]
9. Advances in pathogenesis and therapy of hemolytic uremic syndrome caused by Shiga toxin-2.
Ibarra C; Amaral MM; Palermo MS
IUBMB Life; 2013 Oct; 65(10):827-35. PubMed ID: 24014500
[TBL] [Abstract][Full Text] [Related]
10. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.
Karch H; Friedrich AW; Gerber A; Zimmerhackl LB; Schmidt MA; Bielaszewska M
Semin Thromb Hemost; 2006 Mar; 32(2):105-12. PubMed ID: 16575685
[TBL] [Abstract][Full Text] [Related]
11. Molecular Biology of
Menge C
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32456125
[TBL] [Abstract][Full Text] [Related]
12. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
[TBL] [Abstract][Full Text] [Related]
13. The Fatal Role of Enterohaemorrhagic Escherichia coli Shiga Toxin-associated Extracellular Vesicles in Host Cells.
Lee KS; Park JY; Jeong YJ; Lee MS
J Microbiol; 2023 Aug; 61(8):715-727. PubMed ID: 37665555
[TBL] [Abstract][Full Text] [Related]
14. Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.
Detzner J; Pohlentz G; Müthing J
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32512916
[TBL] [Abstract][Full Text] [Related]
15. Recent Updates on Outbreaks of Shiga Toxin-Producing
Kim JS; Lee MS; Kim JH
Front Cell Infect Microbiol; 2020; 10():273. PubMed ID: 32582571
[TBL] [Abstract][Full Text] [Related]
16. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.
Müthing J; Schweppe CH; Karch H; Friedrich AW
Thromb Haemost; 2009 Feb; 101(2):252-64. PubMed ID: 19190807
[TBL] [Abstract][Full Text] [Related]
17. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome.
Petruzziello-Pellegrini TN; Moslemi-Naeini M; Marsden PA
Virulence; 2013 Aug; 4(6):556-63. PubMed ID: 23955166
[TBL] [Abstract][Full Text] [Related]
18. Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children.
Brigotti M; He X; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Tazzari PL; Ricci F; Patfield SA; Testa S; Paglialonga F; Picicco D; Caprioli A; Scavia G; Morabito S; Ardissino G
Thromb Haemost; 2020 Jan; 120(1):107-120. PubMed ID: 31858520
[TBL] [Abstract][Full Text] [Related]
19. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells.
O'Loughlin EV; Robins-Browne RM
Microbes Infect; 2001 May; 3(6):493-507. PubMed ID: 11377211
[TBL] [Abstract][Full Text] [Related]
20. Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals.
Mainil J
Vet Res; 1999; 30(2-3):235-57. PubMed ID: 10367357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
